Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB) and Coherus Biosciences (CHRS)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Y-Mabs Therapeutics (YMAB) and Coherus Biosciences (CHRS) with bullish sentiments.

Y-Mabs Therapeutics (YMAB)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Y-Mabs Therapeutics, with a price target of $40.00. The company’s shares closed last Monday at $32.99, close to its 52-week high of $34.50.

According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.0% and a 42.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.

Currently, the analyst consensus on Y-Mabs Therapeutics is a Strong Buy with an average price target of $40.00, which is a 17.7% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Coherus Biosciences (CHRS)

Barclays analyst Balaji Prasad maintained a Buy rating on Coherus Biosciences yesterday and set a price target of $33.00. The company’s shares closed last Monday at $17.90.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 12.2% and a 71.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Dr Reddy’s Laboratories, Bausch Health Companies, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $33.60, an 85.2% upside from current levels. In a report issued on November 27, Mizuho Securities also assigned a Buy rating to the stock with a $43.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CHRS:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts